Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Kostas Pantopoulos
Iron deficiency anemia and pre-anemic iron deficiency are the most frequent pathologies. The first line of treatment involves oral iron supplementation. The simplest, least expensive, and most frequently prescribed drug is ferrous sulfate, while other ferrous salts and ferric complexes with polysaccharides or succinylated milk proteins are also widely used. In recent years, novel iron formulations have been developed, such as the lipophilic iron donor ferric maltol, or nanoparticle encapsulated sucrosomial® iron...
April 11, 2024: Haematologica
#22
JOURNAL ARTICLE
Umair Munawar, Johanna Theuersbacher, Maximilian J Steinhardt, Xiang Zhou, Seungbin Han, Silvia Nerreter, Cornelia Vogt, Shilpa Kurian, Thorsten Keller, Ann-Katrin Regensburger, Eva Teufel, Julia Mersi, Max Bittrich, Franziska Seifert, Malik S Haider, Leo Rasche, Jost Hillenkamp, Hermann Einsele, Daniel Kampik, K Martin Kortüm, Johannes M Waldschmidt
Belantamab mafodotin (belantamab) is a first-in-class anti-BCMA antibody-drug conjugate approved for the treatment of triple-class refractory multiple myeloma. It provides a unique therapeutic option for patients ineligible for CAR-T and bispecific antibody therapy, and/or patients progressing on anti-CD38 treatment where CAR-T and bispecifics might be kept in reserve. Wider use of the drug can be challenged by its distinct ocular side effect profile, including corneal microcysts and keratopathy. While dose reduction has been the most effective way to reduce these toxicities, the underlying mechanism of this BCMA off-target effect remains to be characterized...
April 4, 2024: Haematologica
#23
JOURNAL ARTICLE
Christianne Bourlon, Claire Roddie, Tobias Menne, Jane Norman, Maeve O'Reilly, Adam Gibb, Caroline Besley, Sridhar Chaganti, Carlos Gonzalez Arias, Ceri Jones, Abdalla Dikair, Sharon Allen, Frances Seymour, Wendy Osborne, Amrith Mathew, William Townsend, Piers Em Patten, Eleni Thoulouli, Ahmed Abdulgawad, Sanne Lugthart, Robin Sanderson, Amy A Kirkwood, Andrea Kuhnl
Not available.
April 4, 2024: Haematologica
#24
JOURNAL ARTICLE
Tamara De Vos, Nicole Oatman, Lena Boehme, Tom Putteman, Imke Velghe, Yana Van Droogenbroeck, Stijn De Munter, Michaela Cesnekova, Filip Van Nieuwerburgh, Bart Vandekerckhove, Jan Philippe, Tom Taghon
Hematopoiesis is driven by molecular mechanisms that induce differentiation and proliferation of hematopoietic stem cells and their progeny. This involves the activity of various transcription factors, such as members of the Hairy/Enhancer of Split (HES) family, and important roles for both HES1 and HES4 have been shown in normal and malignant hematopoiesis. Here, we investigated the role of HES6 in human hematopoiesis using in vitro and in vivo models. Using bulk and scRNA-seq data, we show that HES6 is expressed during erythroid/megakaryocyte and pDC development, as well as in multipotent precursors and at specific stages of T- and B-cell development following preBCR and preTCR signalling, respectively...
April 4, 2024: Haematologica
#25
JOURNAL ARTICLE
Guru Subramanian Guru Murthy, Antoine N Saliba, Aniko Szabo, Alexandra Harrington, Sameem Abedin, Karen Carlson, Laura Michaelis, Lyndsey Runaas, Arielle Baim, Alex Hinman, Sonia Maldonado-Schmidt, Annapoorna Venkatachalam, Karen S Flatten, Kevin L Peterson, Paula A Schneider, Mark Litzow, Scott H Kaufmann, Ehab Atallah
Azacitidine/venetoclax is an active regimen in patients with newly diagnosed AML. However, primary or secondary resistance to azacitidine/venetoclax is an area of unmet need and overexpression of MCL-1 is suggested to be a potential resistance mechanism. Pevonedistat inhibits MCL-1 through activation of NOXA, and pevonedistat/azacitidine has previously shown activity in AML. To assess the tolerability and efficacy of adding pevonedistat to azacitidine/venetoclax in relapsed/refractory AML, we conducted a phase I multicenter openlabel study in 16 adults with relapsed/refractory AML...
April 4, 2024: Haematologica
#26
JOURNAL ARTICLE
Ozge Ceyhan-Birsoy, Elise Fiala, Satshil Rana, Margaret Sheehan, Jennifer Kennedy, Zarina Yelskaya, Vikas Rai, Yirong Li, Ciyu Yang, Donna Wong, Ivelise Rijo, Jacklyn Casanova, Joshua Somar, Nikita Mehta, Hyeonjin Park, Silvana Ostafi, Kanika Arora, Angelika Padunan, Mark D Ewalt, Umut Aypar, Panieh Terraf, Maksym Misyura, Sofia Haque, Gerald G Behr, Tamanna Haque, Maria Sulis, Mark B Geyer, Christopher Forlenza, Meghan C Thompson, Maria Carlo, Alicia Latham, Ying Liu, Ahmet Zehir, Rose Brannon, Michael Berger, Luis A Diaz, Ahmet Dogan, Marc Ladanyi, Kseniya Petrova-Drus, Khedoudja Nafa, Kenneth Offit, Maria Arcila, Zsofia K Stadler, Michael F Walsh, Diana Mandelker
Not available.
April 4, 2024: Haematologica
#27
JOURNAL ARTICLE
Tonina T Mueller, Mona Pilartz, Manovriti Thakur, Torben LangHeinrich, Junfu Luo, Rebecca Block, Jonathan K L Hoeflinger, Sarah Meister, Flavio Karaj, Laura Garcia Perez, Rupert Öllinger, Thomas Engleitner, Jakob Thoss, Michael Voelkl, Claudia Tersteeg, Uwe Koedel, Alexander Zigman Kohlmaier, Daniel Teupser, Malgorzata Wygrecka, Haifeng Ye, Klaus T Preissner, Helena Radbruch, Sefer Elezkurtaj, Matthias Mack, Philipp Von Hundelshausen, Christian Weber, Steffen Massberg, Christian Schulz, Roland Rad, Samuel Huber, Hellen Ishikawa-Ankerhold, Bernd Engelmann
Innate myeloid cells especially neutrophils and their extracellular traps are known to promote intravascular coagulation and thrombosis formation in infections and various other conditions. Innate myeloid cell dependent fibrin formation can support systemic immunity while its dysregulation enhances the severity of infectious diseases. Less is known about the immune mechanisms preventing dysregulation of fibrin homeostasis in infection. During experimental systemic infections local fibrin deposits in the liver microcirculation cause rapid arrest of CD4+ T cells...
April 4, 2024: Haematologica
#28
JOURNAL ARTICLE
Morgane Denis, Leah Swartzrock, Hana Willner, Quenton R Bubb, Ethan Haslett, Yan Yi Chan, Anzhi Chen, Mark R Krampf, Agnieszka D Czechowicz
Anti-CD117 monoclonal antibody (mAb) agents have emerged as exciting alternative conditioning strategies to traditional genotoxic irradiation or chemotherapy conditioning for both allogeneic and autologous gene-modified hematopoietic stem cell transplantation. Further, these agents are concurrently being explored in the treatment of mast cell disorders. Despite promising results in animal models and more recently in patients, the short-term and long-term effects of these treatments have not been fully explored...
April 4, 2024: Haematologica
#29
JOURNAL ARTICLE
Prithviraj Bose, Lucia Masarova, Naveen Pemmaraju, Sharon D Bledsoe, Naval G Daver, Elias J Jabbour, Tapan M Kadia, Zeev Estrov, Steven M Kornblau, Michael Andreeff, Nitin Jain, Jorge E Cortes, Gautam Borthakur, Yesid Alvarado, Mary Ann Richie, Mackenzie H Dobbins, Selene A McCrackin, Lingsha Zhou, Sherry A Pierce, Xuemei Wang, Allison M Pike, Guillermo Garcia-Manero, Hagop M Kantarjian, Srdan Verstovsek
No abstract text is available yet for this article.
April 4, 2024: Haematologica
#30
JOURNAL ARTICLE
Chi Zhang, Kathy Yuen Yee Chan, Wing Hei Ng, John Tak Kit Cheung, Qiwei Sun, Han Wang, Po Yee Chung, Frankie Wai Tsoi Cheng, Alex Wing Kwan Leung, Xiao-Bing Zhang, Po Yi Lee, Siu Ping Fok, Guanglan Lin, Ellen Ngar Yun Poon, Jian-Hua Feng, Yan-Lai Tang, Xue-Qun Luo, Li-Bin Huang, Wei Kang, Patrick Ming Kuen Tang, Junbin Huang, Chun Chen, Junchao Dong, Ester Mejstrikova, Jiaoyang Cai, Yu Liu, Shuhong Shen, Jun J Yang, Patrick Man Pan Yuen, Chi Kong Li, Kam Tong Leung
Resistance to glucocorticoids (GCs), the common agents for remission induction in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL), poses a significant therapeutic hurdle. Therefore, dissecting the mechanisms shaping GC resistance could lead to new treatment modalities. Here, we showed that CD9- BCP-ALL cells were preferentially resistant to prednisone and dexamethasone over other standard cytotoxic agents. Concordantly, we identified significantly more poor responders to the prednisone prephase among BCP-ALL patients with a CD9- phenotype, especially for those with adverse presenting features including older age, higher white cell count and BCR-ABL1...
April 4, 2024: Haematologica
#31
JOURNAL ARTICLE
Loïs Mougin, Manon Riccetti, Angèle N Merlet, Pablo Bartolucci, Barnabas Gellen, Léo Blervaque, Thomas D'Humières, Frédéric Galactéros, Chi-An W Emhoff, Léonard Féasson, Laurent A Messonnier
Patients with sickle cell disease (SCD) display lower slope coefficients of the oxygen uptake (V_O2) vs. work rate (W) relationship (delineating an O2 uptake/demand mismatch) and a poor metabolic flexibility. Because endurance training (ET) increases the microvascular network and oxidative enzymes activity including one involved in lipid oxidation, ET might improve the slope coefficient of the V_O2 vs. W curve and the metabolic flexibility of SCD patients. ET may also contribute to improve patient post-exercise cardiopulmonary and metabolic recovery...
April 4, 2024: Haematologica
#32
JOURNAL ARTICLE
Kathrin M Bernt
Not available.
April 4, 2024: Haematologica
#33
JOURNAL ARTICLE
Tommaso Francesco Aiello, Jon Salmanton-Garcia, Francesco Marchesi, Barbora Weinbergerova, Andreas Glenthoj, Jens Van Praet, Francesca Farina, Julio Davila-Valls, Sonia Martin-Perez, Shaimaa El-Ashwah, Martin Schonlein, Iker Falces-Romero, Jorge Labrador, Uluhan Sili, Caterina Buquicchio, Antonio Vena, Gaetan Plantefeve, Verena Petzer, Monika M Biernat, Tobias Lahmer, Ildefonso Espigado, Jaap Van Doesum, Ola Blennow, Klara Piukovics, Carlo Tascini, Michail Samarkos, Yavuz M Bilgin, Luana Fianchi, Federico Itri, Toni Valković, Nicola S Fracchiolla, Michelina Dargenio, Moraima Jimenez, Ferenc Magyari, Alberto Lopez-Garcia, Lucia Prezioso, Natasha Čolović, Evgenii Shumilov, Ghaith Abu-Zeinah, Carolin Krekeler, Esperanza Lavilla-Rubira, Mario Virgilio Papa, Tomas Jose Gonzalez-Lopez, Laszlo Imre Pinczes, Fatih Demirkan, Natasha Ali, Caroline Besson, Guillemette Fouquet, Alessandra Romano, Jose-Angel Hernandez-Rivas, Maria Ilaria Del Principe, Avinash Aujayeb, Maria Merelli, Sylvain Lamure, Joyce Marques De Almeida, Maria Gomes Da Silva, Noha Eisa, Joseph Meletiadis, Ikhwan Rinaldi, Olimpia Finizio, Ozren Jaksic, Mario Delia, Summiya Nizamuddin, Monia Marchetti, Marriyam Ijaz, Marina Machado, Rebeca Bailen-Almorox, Martin Čerňan, Nicola Coppola, Eleni Gavriilaki, Chiara Cattaneo, Ana Groh, Zlate Stojanoski, Nurettin Erben, Nicola Pantic, Gustavo-Adolfo Mendez, Roberta Di Blasi, Stef Meers, Cristina De Ramon, Nathan C Bahr, Ziad Emarah, Gina Varricchio, Milche Cvetanoski, Ramon Garcia-Sanz, Mirjana Mitrovic, Raphael Lievin, Michaela Hanakova, Zdeněk Račil, Maria Vehreschild, Athanasios Tragiannidis, Raquel Nunes Rodrigues, Daniel Garcia-Bordallo, Raul Cordoba, Alba Cabirta, Anna Nordlander, Emanuele Ammatuna, Elena Arellano, Dominik Wolf, Romane Prin, Alessandro Limongelli, Martina Bavastro, Gokce Melis Colak, Stefanie Grafe, Ditte Stampe Hersby, Laman Rahimli, Oliver A Cornely, Carolina Garcia-Vidal, Livio Pagano
Not available.
April 4, 2024: Haematologica
#34
JOURNAL ARTICLE
Daisuke Ikeda, Mitsuaki Oura, Atsushi Uehara, Rikako Tabata, Kentaro Narita, Masami Takeuchi, Youichi Machida, Kosei Matsue
To elucidate the relationship between pre-treatment radiomic parameters and the proportions of various tumour-infiltrating (TI) cells, we retrospectively analysed the association of total metabolic tumour volume (TMTV) and TI cells on biopsied tumour lesions in 171 patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). The surface markers of TI cells were analysed by multicolour flow cytometry using a dissected single-cell suspension. In examining the correlation between TI cells and PET-derived parameters (SUVmax, TMTV, and total lesion glycolysis), intratumoural cell types minimally influenced the results, except for a weak negative correlation between CD4+ cells and SUVmax (R=-0...
April 4, 2024: Haematologica
#35
JOURNAL ARTICLE
Jyoti Kumar, Natasha E Lewis, Sarina Sherpa, Dory Londono, Xiaotian Sun, Qi Gao, Maria E Arcila, Mikhail Roshal, Yanming Zhang, Wenbin Xiao, Alexander Chan
Not available.
April 4, 2024: Haematologica
#36
JOURNAL ARTICLE
Markus Perl, Konstantin Herfeld, Dennis C Harrer, Matthias Höpting, Marina Schweiger, Ulrich Sterz, Leonard Knödler, Susanne Heimerl, Leo Hansmann, Wolfgang Herr, Hendrik Poeck, Daniel Wolff, Matthias Edinger, Christina Hart, Matthias A Fante
Chimeric antigen receptor (CAR-) T cell therapy causes serious side effects including cytokine release syndrome (CRS). CRS-related coagulopathy is associated with hypofibrinogenemia that is thus far considered the result of disseminated intravascular coagulation (DIC) and liver dysfunction. We investigated incidence and risk factors for hypofibrinogenemia in 41 consecutive adult patients with hematologic malignancies (median age 69 years, range 38-83 years) receiving CAR-T cell therapy between 01/2020 and 05/2023 at the University Medical Center Regensburg...
March 28, 2024: Haematologica
#37
JOURNAL ARTICLE
Laurent Garderet, Luuk Gras, Linda Koster, Liesbeth De Wreede, Rovira Montserrat, Laure Vincent, Roland Fenk, Kamaraj Karunanithi, Dries Deeren, Martin Kaufmann, Jürgen Kuball, Hakan Ozdogu, Maria Jesus Pascual Cascon, Jakob Passweg, Adam Rye, Urpu Salmenniemi, John Snowden, Charlotte Toftmann Hansen, Xavier Leleu, Lauris Gastaud, Joanna Drozd Sokolowska, Kavita Raj, Meral Beksac, Stefan Schönland, Patrick Hayden, Donal McLornan
There is little long-term outcome data on the efficacy of autologous hematopoietic stem cell transplantation (ASCT) in light chain deposition disease (LCDD). We identified 51 LCDD patients in the EBMT registry who had undergone upfront ASCT between 1995 and 2021. The median serum creatinine was 280 μmol/L and 45% required renal replacement therapy (RRT) at time of transplant. The melphalan dose was 100mg/m2 in 23%, 140mg/m2 in 55% and 200 mg/m2 in 21%. The rate of very good partial response or better improved from 41% pre-transplant to 66% at Day +100 post-ASCT...
March 28, 2024: Haematologica
#38
JOURNAL ARTICLE
Ana Cristina Martins, Jean-Baptiste Gibier, Charles Ronsin, Christine Kandel-Aznar, Anne Moreau, Marion Chapal, Diogo Francisco, Hamza Sakhi, Julie Oniszczuk, Lorraine Gueguen, Anne Grunenwald, Mathilde Devaux, Alexandre Karras, Virginie Royal, Marion Rabant, Viviane Gnemmi, Jérôme Olagne, Jean-Paul Duong Van Huyen, Pierre Isnard
Not available.
March 28, 2024: Haematologica
#39
JOURNAL ARTICLE
Do Hwan Kim, Sa A Wang, Wei Wang, Guilin Tang, Shaoying Li, C Cameron Yin, Pei Lin, Marina Konopleva, M James You, Roberto N Miranda, Xiaoqiong Wang, Qing Wei, L Jeffrey Medeiros, Jie Xu
Not available.
March 28, 2024: Haematologica
#40
JOURNAL ARTICLE
Nickolas Steinauer, Kristen McCullough, Aref Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Abhishek A Mangaonkar, Antoine N Saliba, Mehrdad Torghabeh, Mark R Litzow, William J Hogan, Mithun Shah, Mrinal M Patnaik, Animesh Pardanani, Talha Badar, Hemant Murthy, James Foran, Cecilia Arana Yi, Ayalew Tefferi, Naseema Gangat
Not available.
March 28, 2024: Haematologica
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
